Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer

Published:2021-01-26 Issue:1 Volume:4 Page:e2034633
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Vaishampayan Ulka N.¹²,Heilbrun Lance K.¹,Monk Paul³,Tejwani Sheela⁴,Sonpavde Guru⁵,Hwang Clara⁴,Smith Daryn¹,Jasti Pallavi⁶,Dobson Kimberlee¹,Dickow Brenda¹,Heath Elisabeth I.¹,Semaan Louie⁷,Cher Michael L.¹⁷,Fontana Joseph A.¹,Chinni Sreenivasa¹⁷

Affiliation:

1. Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan

2. Department of Internal Medicine, University of Michigan, Ann Arbor

3. Department of Internal Medicine, The Ohio State University, Columbus

4. Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan

5. Department of Internal Medicine, Dana Farber Cancer Institute, Boston, Massachusetts

6. John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan

7. Department of Urology, Wayne State University, Detroit, Michigan

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2775631/vaishampayan_2021_oi_201051_1613755588.50004.pdf

Reference21 articles.

1. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.;Schalken;BJU Int,2016

2. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.;Shore;Lancet Oncol,2016

3. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.;Sweeney;N Engl J Med,2015

4. Abiraterone for prostate cancer not previously treated with hormone therapy.;James;N Engl J Med,2017

5. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.;Fizazi;N Engl J Med,2017

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis;British Journal of Cancer;2024-09-02

2. Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer;JAMA Oncology;2024-07-01

3. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world;Frontiers in Oncology;2024-04-18

4. Research protocol for an observational health data analysis to assess the applicability of randomized controlled trials focusing on newly diagnosed metastatic prostate cancer using real-world data: PIONEER IMI’s “big data for better outcomes” program;International Journal of Surgery Protocols;2024-04-15

5. A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs appropriately?;Critical Reviews in Oncology/Hematology;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3